News
SVRA
6.03
+2.20%
0.13
Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?
Simply Wall St · 6h ago
Weekly Report: what happened at SVRA last week (0622-0626)?
Weekly Report · 16h ago
Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?
Simply Wall St · 1d ago
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
The Motley Fool · 2d ago
Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million
PUBT · 06/23 00:18
Weekly Report: what happened at SVRA last week (0615-0619)?
Weekly Report · 06/22 09:22
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?
Simply Wall St · 06/20 19:24
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
TipRanks · 06/15 14:30
Weekly Report: what happened at SVRA last week (0608-0612)?
Weekly Report · 06/15 09:22
Savara (SVRA) Stock Valuation After CFO Transition And Leadership Change
Simply Wall St · 06/14 11:19
Savara grants new-hire equity awards for 87,000 shares, options priced at $5.27
PUBT · 06/12 20:05
Savara Announces New Employment Inducement Grant
Barchart · 06/12 15:05
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role
Simply Wall St · 06/11 04:44
Savara Earns Buy Rating on Strengthened Leadership and High Confidence in MOLBREEVI’s Regulatory Path and Commercial Potential
TipRanks · 06/09 11:25
Savara CFO Steps Down Citing Health-Related Reasons
Dow Jones · 06/08 21:59
Savara Expands Share Capital and Updates Executive Leadership
TipRanks · 06/08 21:48
Savara CFO to step down
Seeking Alpha · 06/08 20:27
*Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA
Dow Jones · 06/08 20:17
Savara shareholders approve charter amendment doubling authorized common shares to 600 million
PUBT · 06/08 20:16
Savara says CFO Dave Lowrance stepping down for health reasons
TipRanks · 06/08 20:12
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.